Skip to main content
. 2018 Sep 12;12:2923–2931. doi: 10.2147/DDDT.S168218

Figure 3.

Figure 3

In vitro drug diffusion, *p<0.05 **p<0.01 ***p<0.001 vs 4w/w% PaHCl-LLC (A) and ex vivo skin penetration, **p<0.01 ***p<0.001 vs 3w/w% PaHCl-LLC (B) studies.

Abbreviations: PaHCl, papaverine hydrochloride; LLC, lyotropic liquid crystal.